Browse

Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.